Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.

Publication date: Feb 28, 2024

Under the global risk of epidemic rebound of influenza after COVID-19 outbreak, the study aimed to provide a comprehensive evaluation of the seasonal influenza vaccine effectiveness (IVE) and to explore the potential effect modifiers. We searched for test-negative design studies with IVE estimates published between January 1, 2017 and December 31, 2022. We estimated pooled IVE using random-effects meta-analysis, and conducted meta-regression with study site, age, sex and comorbidity as explanatory variables. We identified 2429 publications and included 191 in the meta-analysis. The pooled IVE was 41. 4 % (95 % CI: 39. 2-43. 5 %) against any influenza. For specific strains, the IVE was 55. 4 % (95 % CI: 52. 7-58. 1 %) against A/H1N1, 26. 8 % (95 % CI: 23. 5-29. 9 %) against A/H3N2, 47. 2 % (95 % CI: 38. 1-54. 9 %) against B/Yamagata, and 40. 6 % (95 % CI: 23. 7-53. 7 %) against B/Victoria, and the effectiveness against A/H3N2 was significantly lower than A/H1N1 (p

Concepts Keywords
Global Influenza
Influenza Meta-regression
January Systematic review
Vaccination Test-negative design
Vaccine effectiveness

Semantics

Type Source Name
disease VO effectiveness
disease VO Optaflu
disease MESH influenza
disease VO vaccination
disease MESH COVID-19
disease VO vaccine effectiveness
disease IDO site
disease MESH comorbidity

Original Article

(Visited 1 times, 1 visits today)